• Publications
  • Influence
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
TLDR
This work uses gene expression data to describe four molecular subtypes linked to distinct patterns of molecular alterations, disease progression and prognosis in gastric cancer, and describes key molecular alterations in each of the four subtypes using targeted sequencing and genome-wide copy number microarrays.
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:
TLDR
The addition of XRT to XP chemotherapy did not significantly reduce recurrence after curative resection and D2 lymph node dissection in Gastric cancer and a subsequent trial (ARTIST-II) in patients with lymph node-positive gastric cancer is planned.
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
TLDR
Although no significant difference in progression-free survival was noted between groups, the addition of erlotinib to gemcitabine and oxaliplatin showed antitumour activity and might be a treatment option for patients with cholangiocarcinoma.
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
TLDR
Findings provide insight into the molecular features associated with response to pembrolizumab in patients with mGC and provide biomarkers potentially relevant for the selection of patients who may derive greater benefit from PD-1 inhibition.
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach
  • S. Park, T. Sohn, +14 authors W. Kang
  • Medicine
    Journal of clinical oncology : official journal…
  • 5 January 2015
TLDR
In D2-resected GC, both adjuvant chemotherapy and chemoradiotherapy are tolerated and equally beneficial in preventing relapse.
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
  • J. Kang, S. Lee, +13 authors S. Park
  • Medicine
    Journal of clinical oncology : official journal…
  • 12 March 2012
TLDR
To the authors' knowledge, this is the largest phase III trial comparing SLC plus BSC with BSC alone in AGC and in pretreated patients, SLC is tolerated and significantly improves OS when added to BSC.
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
TLDR
Entrectinib was shown to be well tolerated and active against those gene fusions in solid tumors, including in patients with primary or secondary CNS disease, and a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
TLDR
Pembrolizumab did not significantly improve overall survival compared with paclitaxel as second-line therapy for advanced gastric or gastro-oesophageal junction cancer with PD-L1 CPS of 1 or higher and had a better safety profile than pac litaxel.
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
TLDR
The analytic and clinical validation of the gene panel are reported and near-perfect analytic specificity enables complete coverage of many genes without the false positives typically seen with traditional sequencing assays at mutant allele frequencies or fractions below 5%.
Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.
TLDR
The results suggest that the increased MET copy number measured by qPCR plays an important role in determining prognosis in gastric cancer patients, however, the predictive role of MET amplification for treatment response should be further explored in upcoming clinical trials.
...
1
2
3
4
5
...